市場調查報告書
商品編碼
1463622
南美洲和中美洲生物製藥凍乾服務市場預測至 2028 年 - 區域分析 - 按服務類型和最終用戶South & Central America Lyophilization Services for Biopharmaceuticals Market Forecast to 2028 - Regional Analysis - by Service Type and End-User |
2023年南美洲和中美洲生物製藥凍乾服務市場價值為7002萬美元,預計到2028年將達到1.0437億美元;預計 2023 年至 2028 年CAGR為 8.3%。
合約製造和冷凍乾燥服務的快速成長推動了南美洲和中美洲生物製藥市場的冷凍乾燥服務
生物製藥市場在全球持續擴張,這可能成為製藥業的主要成長動力。隨著更多治療性生物製劑獲得批准,生物製藥腸外生產最近有所擴大。生物技術公司從合約製造組織 (CMO) 外包,以滿足其填充和加工需求並降低微生物污染的風險。生物製藥公司依賴合約製造組織 (CMO) 來提供所需的產能和能力;在某些情況下,CMO 提供公司大量的產品。
建立內部凍乾能力和操作需要專門的設備和專業知識,這是昂貴且耗時的。然而,外包成本更低,並且提高了製造流程的效率。此外,它還允許生物技術公司將資源重新分配到其他領域。因此,藥物開發商和生物製藥公司將此類業務外包給 CMO,以節省整體生產和產量成本。幾年前,CMO 產業是一個利基服務市場,為生物技術公司提供額外的製造能力或特定服務。現在,許多生技公司外包各種服務,從早期藥物開發到商業規模製造。隨著生技產業從大規模生產轉向小眾、標靶治療(個人化醫療),對靈活營運能力、生產規模和多產品營運的需求不斷上升。由於所有這些因素,對 CMO 的傾向正在成長。因此,生物製藥 CMO 的能力和可用性不斷提高,推動了南美洲和中美洲凍乾服務的生物製藥市場成長。
南美洲和中美洲生物製藥凍乾服務市場概述
南美洲和中美洲地區包括巴西、阿根廷以及南美洲和中美洲的其他地區。預計巴西將在該地區佔據主要市場佔有率。由於製藥和生物製藥行業的巨大研發投資,市場可能有良好的成長機會。此外,與外國當局和組織的合作可能需要這些國家的凍乾服務。
南美洲和中美洲生物製藥凍乾服務市場收入及 2028 年預測(百萬美元)
南美洲和中美洲生物製藥凍乾服務市場細分
南美洲和中美洲生物製藥市場的冷凍乾燥服務按服務類型、最終用戶和國家進行細分。
根據服務類型,南美洲和中美洲生物製藥市場凍乾服務分為冷凍乾燥循環開發、臨床製造、商業製造和冷凍乾燥分析服務。 2023 年,商業製造領域佔據最大的市場佔有率。
根據最終用戶,南美洲和中美洲生物製藥市場凍乾服務分為製藥和生技公司、研究機構等。 2023 年,製藥和生技公司細分市場佔據最大的市場。
根據國家/地區,南美洲和中美洲生物製藥市場的冷凍乾燥服務分為巴西、阿根廷以及南美洲和中美洲其他地區。 2023 年,巴西在南美洲和中美洲生物製藥凍乾服務市場佔有率中佔據主導地位。
ABB、Azbil Corporation、Curia Global Inc、Grifols SA、Jubilant HollisterStier LLC. 和 OPTIMA 是南美洲和中美洲生物製藥市場凍乾服務領域的一些領先公司。
The South & Central America lyophilization services for biopharmaceuticals market was valued at US$ 70.02 million in 2023 and is expected to reach US$ 104.37 million by 2028; it is estimated to grow at a CAGR of 8.3% from 2023 to 2028.
Rapid Growth in Contract Manufacturing and Lyophilization Services Fuels the South & Central America Lyophilization Services for Biopharmaceuticals Market
The biopharmaceuticals market continues to expand across the world, which can be the primary growth driver for the pharmaceutical industry. Biopharmaceutical parenteral manufacturing has expanded recently as more therapeutic biologics have been approved. Biotechnology companies outsource from contract manufacturing organizations (CMOs) to meet their fill-and-finish needs and reduce the risk of microbial contamination. Biopharma companies are dependent on contract manufacturing organizations (CMOs) to provide capacity and capabilities as needed; in some cases, CMOs provide a great deal of a company's production.
Setting up in-house lyophilization capabilities and operations requires specialized equipment and expertise, which is an expensive and time-consuming. However, outsourcing is cheaper and increases the efficiency of manufacturing processes. Additionally, it allows biotechnology companies to redirect resources to other areas. Thus, drug developers and biopharmaceutical companies outsource such operations to CMOs to save overall production and yield cost. A few years ago, the CMO industry was a niche service market, offering additional manufacturing capacity or specific services to biotechnology companies. Now, many biotechnology companies outsource various services, from early-stage drug development to commercial-scale manufacturing. As the biotechnology industry is shifting from large-scale production to niche and targeted therapies (personalized medicine), the demand for flexible operational capabilities, production scales, and multiple-product operations is rising. Owing to all these factors, the inclination toward CMOs is growing. Thus, the rising capability and availability of biopharma CMOs fuel the South & Central America lyophilization service for biopharmaceuticals market growth.
South & Central America Lyophilization Services for Biopharmaceuticals Market Overview
South and Central America region consist of Brazil, Argentina, and the Rest of the South and Central America. Brazil is expected to have a major market share in this region. The market is likely to have good growth opportunities owing to the huge investment for research and development in the pharmaceutical and biopharmaceutical industry. In addition, the collaboration with foreign authorities and organizations is likely to demand the lyophilization services in the countries.
South & Central America Lyophilization Services for Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Mn)
South & Central America Lyophilization Services for Biopharmaceuticals Market Segmentation
The South & Central America lyophilization services for biopharmaceuticals market is segmented service type, end user, and country.
Based on service type, the South & Central America lyophilization services for biopharmaceuticals market is segmented into lyophilization cycle development, clinical manufacturing, commercial manufacturing, and freeze drying analytical services. The commercial manufacturing segment held the largest market share in 2023.
Based on end-user, the South & Central America lyophilization services for biopharmaceuticals market is segmented into pharmaceutical & biotechnology companies, research institutes, and other. The pharmaceutical & biotechnology companies segment held the largest market share in 2023.
Based on country, the South & Central America lyophilization services for biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America lyophilization services for biopharmaceuticals market share in 2023.
ABB, Azbil Corporation, Curia Global Inc, Grifols S.A., Jubilant HollisterStier LLC., and OPTIMA are some of the leading companies operating in the South & Central America lyophilization services for biopharmaceuticals market.